Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025

Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) announced eight abstracts accepted for The Liver Meeting® 2025 (Nov 7–11, 2025), including one oral presentation on 96-week and post-treatment follow-up data from the Phase 1 monotherapy study of ALG-000184, a capsid assembly modulator for chronic hepatitis B (HBV).

Highlights include an oral session on Nov 9, 2025 reporting that once-daily 300 mg ALG-000184 "demonstrates potent suppression of HBV DNA," a poster reporting sustained reduction of HBV antigen levels during an 8-week follow-up after 96 weeks of treatment, and multiple preclinical posters on CAM compounds and siRNA candidates for liver disease.

Positive

• Phase 1 ALG-000184 96-week and post-treatment data will be presented
• Oral presentation reports potent suppression of HBV DNA with 300 mg ALG-000184
• Poster reports sustained HBV antigen reduction during 8-week follow-up after 96 weeks
• Eight abstracts accepted across clinical and preclinical HBV and MASLD/MASH programs

Negative

• Data described without numeric efficacy or safety values in this announcement
• ALG-000184 remains in Phase 1, limiting near-term commercialization certainty

Insights

Hepatology drug development expert

Early clinical signals for ALG-000184 show sustained antiviral and antigen reductions through long follow-up, suggesting promising Phase 1 efficacy signals.

Aligos's oral presentation of full 96-week and post-treatment follow-up data shows continued suppression of HBV DNA and sustained antigen reductions after stopping 300 mg ALG-000184. This describes a mechanism where a capsid assembly modulator (CAM-E) reduces viral replication and antigenemia, which are direct, measurable pharmacodynamic effects relevant to functional cure strategies in chronic HBV.

The observations rest on disclosed Phase 1 monotherapy data and preclinical posters on related CAM and RNA assets; however, the clinical impact depends on durability across larger, controlled cohorts and safety/tolerability findings, which are not provided here. The material is factual but incomplete: absence of adverse event details, statistical measures, and comparator data limits definitive interpretation.

Watch the oral session on November 9, 2025 for full efficacy and safety tables and the poster session on November 7, 2025 for antigen follow-up details. Key items to monitor over the next 3–12 months include whether the 96-week dataset includes safety signals, responder rates, viral rebound patterns in the 8-week off-treatment window, and plans for controlled Phase 2 studies.

Oral presentation will include the full 96-week and post-treatment follow up data from the Phase 1 monotherapy study of ALG-000184

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced eight presentations, including one oral presentation, at The Liver Meeting^® 2025, being held November 7 – 11, 2025 in Washington, D.C. The abstracts released today can be found on the AASLD website at https://www.aasld.org/the-liver-meeting.

Details on the abstracts are as follows:

ALG-000184: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection

Publication #: 0198
Type: Oral Presentation
Title: Oral Once -Daily 300 mg ALG-000184, a Novel Capsid Assembly Modulator Demonstrates potent suppression of HBV DNA in Treatment-Naive or Currently-not-treated Subjects with Chronic HBV
Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong
Date/Time: November 9, 2025 at 5:00pm – 6:30pm ET
Session: Next-generation HBV Therapeutics: Emerging Therapies and Search for Functional Cure

Publication #: 1208
Type: Poster Presentation
Title: Sustained Reduction of HBV Antigen Levels During the 8-Week Follow-up Period in Treatment Naïve (TN) or Currently-Not-Treated (CNT) HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection After 96-Week 300 mg ALG-000184
Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong
Date/Time: November 7, 2025 at 8:00am – 5:00pm ET
Session: Hepatitis B (“1118-1367”)

Publication #: 1251
Type: Poster Presentation
Title: Capsid Assembly Modulator ALG-001075 Prevents cccDNA Formation and HBV DNA Integration In Vitro
Presenter: Jordi Verheyen
Date/Time: November 7, 2025 at 8:00am – 5:00pm ET
Session: Hepatitis B (“1118-1367”) 

Publication #: 1338
Type: Poster Presentation
Title: Capsid Assembly Modulator ALG-001075 Binds and Directly Targets HBeAg
Presenter: Jordi Verheyen
Date/Time: November 7, 2025 at 8:00am – 5:00pm ET
Session: Hepatitis B (“1118-1367”)

Preclinical

Publication #: 1248
Type: Poster Presentation
Title: Differentiation of HBV capsid assembly modulators based on stabilization of core protein oligomerization and residence time
Presenter: Cheng Liu, PhD
Date/Time: November 7, 2025 at 8:00am – 5:00pm ET
Session: Hepatitis B (“1118-1367”)

Publication #: 1330
Type: Poster Presentation
Title: CAM-E and CAM-A Compounds Differentially Affect Phosphorylated and Non-Phosphorylated Hepatitis B Core Protein In Vitro
Presenter: Rene Geissler, PhD, Abbott Diagnostics Division
Date/Time: November 7, 2025 at 8:00am – 5:00pm ET
Session: Hepatitis B (“1118-1367”)

Publication #: 1155
Type: Poster Presentation
Title: Lead Optimization and Selection of a Potential Best-in-Class HBV ASO
Presenter: Jin Hong, PhD
Date/Time: November 7, 2025 at 8:00am – 5:00pm ET
Session: Hepatitis B (“1118-1367”)

Publication #: 1103
Type: Poster Presentation
Title: Two Pre-clinical Short Interfering RNA Molecules Targeting Human HSD17beta13 for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
Presenter: Jieun Song, PhD
Date/Time: November 7, 2025 at 8:00am – 5:00pm ET
Session: MASLD/MASH - Experimental: Basic ("1001-1117")

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Investor Contact
Aligos Therapeutics, Inc.
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com

Media Contact
Inizio Evoke
Jake Robison
Vice President
Jake.Robison@inizioevoke.com

FAQ

What will Aligos (ALGS) present about ALG-000184 at The Liver Meeting 2025?

An oral presentation on Nov 9, 2025 will present full 96-week and post-treatment Phase 1 monotherapy data for 300 mg ALG-000184, reporting potent HBV DNA suppression.

When and where will Aligos present the ALG-000184 oral data (ALGS)?

The oral presentation is scheduled for Nov 9, 2025, 5:00pm–6:30pm ET at The Liver Meeting in Washington, D.C.

Does the Aligos press release include numerical efficacy or safety results for ALGS programs?

No; the announcement describes outcomes (suppression and sustained antigen reductions) but does not provide numeric efficacy or safety values.

How many Aligos abstracts (ALGS) were accepted at The Liver Meeting 2025 and what topics do they cover?

Eight abstracts were accepted covering ALG-000184 clinical data, multiple capsid assembly modulator preclinical studies, and two siRNA preclinical candidates for MASLD/MASH.

What is the development stage of ALG-000184 mentioned by Aligos (ALGS)?

ALG-000184 is in Phase 1 clinical development with 96-week monotherapy and post-treatment follow-up data reported for presentation.

Will investors be able to view Aligos presentations (ALGS) from The Liver Meeting 2025?

Abstracts are posted on the AASLD website and sessions occur Nov 7–11, 2025; check the AASLD program for poster locations and oral session details.